Skip to main content
VCbacked
Log inGet Started

Atavistik Bio

Cambridge, United States

Atavistik Bio is a biotechnology company that develops precision allosteric small molecules aimed at treating metabolic diseases and cancer.

$40.0M raised
Mar 2026
Series B
BiotechnologyHealth CareLife ScienceTherapeutics

Top Investors

RA Capital ManagementLux CapitalThe Column GroupNextech InvestRegeneron Ventures

Founder Contacts

30,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Atavistik Bio

How much funding has Atavistik Bio raised?
Atavistik Bio has raised $40.0M in total funding. The most recent round was Series B. The last funding was announced in March 2026.
Who are Atavistik Bio's investors?
Atavistik Bio's investors include RA Capital Management, Lux Capital, The Column Group, Nextech Invest, Regeneron Ventures.
Where is Atavistik Bio headquartered?
Atavistik Bio is headquartered in Cambridge, United States.
What does Atavistik Bio do?
Atavistik Bio is a biotechnology company that develops precision allosteric small molecules aimed at treating metabolic diseases and cancer.
What stage is Atavistik Bio at?
Atavistik Bio is at the Series B stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Atavistik Bio — Funding & Investors." VCBacked, March 5, 2026, https://www.vcbacked.co/company/atavistik-bio. Accessed July 2, 2026.
APA
VCBacked. (2026). Atavistik Bio — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/atavistik-bio
Wikipedia (cite web)
{{cite web |title=Atavistik Bio — Funding & Investors |url=https://www.vcbacked.co/company/atavistik-bio |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Allterum Therapeutics
Houston$1.0M
Renaissance BioScience
Vancouver$599K
AlpalifeBio
Woburn$9.8M
Rapport Therapeutics
Boston$250.0M
Epsilogen
London$16.3M
Advanced Microbiome Interventions
Amsterdam$300K